Pfizer to Showcase Breakthrough Data on Infectious Disease Portfolio Including RSV, Influenza, and COVID-19 at IDWeek 2023

Oct 10, 2023 07:20 CST Updated 07:20

Pfizer

Pharmaceutical R&D Developer

▲October 21, General Cell Drug Development Forum · Free for a limited timeRegistration ongoing

October 10, 2023 / eMedClub News /--Pfizer to Present Data from its Infectious Disease Portfolio at IDWeek 2023, the Joint Annual Meeting on Infectious Diseases organized by the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, and others, to be held in Boston from October 11-15.Data from 45 abstracts from Pfizer will highlight its progress in helping to prevent and treat certain infectious diseases, particularly respiratory illnesses, including those previously evaluated in the IDWeek news program.ABRYSVO™A Study on the Potential Public Health Impact of Pfizer's Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine for Maternal Immunization to Protect Infants from RSV.

Pfizer will present breakthrough research on the company's robust infectious disease portfolio at IDWeek 2023, including RSV, COVID-19, pneumococcal disease, Lyme disease, meningococcal disease, and multidrug-resistant Gram-negative bacterial infections. Eight abstracts have been selected for oral presentation, includingData on the Successful Co-administration of Abrysvo (RSVpreF, PF-06928316) and Influenza Vaccine in the Elderly, the tolerability and safety of the 20-valent pneumococcal conjugate vaccine (PCV20) in infants and older children from global studies. In addition, Pfizer will present the Phase 3 study results of the investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in a poster presentation, along with new data on the FDA-approved oral treatment for adults with COVID-19, PAXLOVID™.

Pfizer to Deliver Oral Presentations on Eight Abstracts,▲ Image Source:HuiPfizer Official Website

$78 Billion RSV Market,

Pfizer Breaks Through with Differentiated Competition Across the Entire Population

eMedClub

Respiratory Syncytial Virus (RSV) is a common respiratory virus that can cause lower respiratory tract disease (LRTD) and, in severe cases, can be fatal.According to statistics, the global annual incidence rate of RSV is approximately 3~10%, and about 102,000 children die from RSV infection each year.Elderly people are also at high risk of severe RSV-related diseases due to age-related decline in immunity and underlying medical conditions.According to the report data published by Research and Markets in October 2023,It is estimated that by 2030, the global RSV treatment drug market will soar from US$1 billion in 2022 to an astonishing US$7.8 billion.During the analysis period from 2022 to 203029.2%with a compound annual growth rate.China is the world's second-largest economy, and its market size is expected to reach by 2030.$1.3 billion, with a compound annual growth rate of 28% during the analysis period from 2022 to 2030.In the field of RSV vaccine development, Pfizer, GSK, and Moderna have formed a tripartite competitive landscape.

Global RSV Treatment Drug Market,▲ Image Source:Research and Markets Official Website

On May 4, GSK's bivalent RSV vaccine GSK3844766A (RSVPreF3 OA) was approved for marketing by the FDA.GSK3844766A, composed of the prefusion F glycoprotein (RSVPreF3) combined with GSK's proprietary adjuvant, has become the first vaccine for preventing lower respiratory tract disease caused by RSV infection in adults aged 60 and above. Results from the pivotal Phase III AReSVi-006 study, which included 25,000 patients, showed an overall vaccine efficacy of 82.6% against RSV-LRTD, meeting the primary endpoint. The efficacy in preventing severe RSV-LRTD was 94.1%. Among individuals with underlying comorbidities, the vaccine efficacy was 94.6%, with 93.8% observed in the 70-79 age group. Additionally, the vaccine demonstrated consistent efficacy in preventing LRTD caused by both RSV-A and RSV-B infections, at 84.6% and 80.9%, respectively.

On May 31, Pfizer announced that the FDA had approved its bivalent RSV vaccine.Abrysvo(RSVpreF, PF-06928316) Launch, a bivalent recombinant subunit vaccine composed of equal amounts of prefusion F (preF) antigens from RSV A and RSV B subtypes, is used to prevent lower respiratory tract diseases caused by RSV in individuals aged 60 years and above, becoming the second approved RSV vaccine.On August 21, Abrysvo's new indication received FDA approval for the prevention of RSV-related lower respiratory tract disease in infants from birth to 6 months of age through active immunization of pregnant women. This is the first infant RSV vaccine approved by the FDA.In addition to the two approved indications, Pfizer has initiated two new Phase III clinical trials for ABRYSVO, aiming to evaluate the vaccine's safety, tolerability, and immunogenicity in preventing RSV infection in high-risk adult populations and in children aged 2 to under 18 who are at high risk for RSV.Pfizer Intends toAbrysvoApplied to patients of all age groups, thereby increasing market share.

Moderna's mRNA-1345 is also used to prevent RSV-LRTD and acute respiratory disease (ARD) in adults aged 60 years or older. This is a monovalent mRNA vaccine encoding the pre-fusion F glycoprotein of RSV., compared with the post-fusion state, it can elicit a higher neutralizing antibody response. On July 5, Moderna announced the submission of a global marketing application for mRNA-1345, including filings in the EU, Switzerland, and Australia, as well as the initiation of a rolling submission to the FDA. The anticipated PDUFA date is April 2024.

In the past three years, Pfizer has developed several innovative vaccines and therapeutic drugs for infectious diseases. The burden of respiratory diseases on global public health is undoubtedly enormous. As the Northern Hemisphere is about to enter the winter flu season, people are once again facing the threat of triple infections from influenza, RSV, and COVID-19. During this critical period, Pfizer's vaccines and therapeutic drugs can help mitigate the impact of certain respiratory infections.

References:

1.https://www.researchandmarkets.com/report/rsv-drug

2.https://www.pfizer.com

Exciting Live Broadcast Preview

Press and hold to scan the QR code and participate immediately ↓

Recommendation

October 10 (Tuesday) 19:00-21:00

Expand CGT's Differentiated Competitive Advantage through Innovation-Driven Strategies

Recommendation

October 18th (Wednesday) 14:00-15:30

The Dormant mRNA: Quality is the Key to Success

Statement and Copyright Notice

Disclaimer: This article aims to convey industry development information and explore the frontier progress of biopharmaceuticals. The content of the article represents the author's viewpoint and does not represent the position of E-Medical, nor does it constitute any value judgment, investment advice, or medical guidance. If needed, please consult a professional for investment or visit a正规 hospital for medical advice.

Copyright Statement:This article is from the content team of Yima Guest. Individuals are welcome to share it on their social media, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization, please leave a message at the bottom of the article.

Dian Dian "Share”、“Like" and "In view"，Give me a little recharge, please~